OBJECTIVE: To describe gender differences in injection and sexual risks behaviours, and human immunodeficiency virus (HIV) and hepatitis C (HCV) prevalence among injecting drug users (IDU) in Catalonia, Spain. METHODS: Cross-sectional studies in 2008-2009 (n=748) and 2010-2011 (n=597) in the network of harm reduction centres. Face to face interviews were conducted and oral fluid samples were collected to estimate HIV/HCV prevalence. RESULTS: Female were more likely than male IDU to have had a steady sexual partner (68.2% versus 44.9%), to have had an IDU steady sexual partner (46.6% versus 15.1%) and to have exchanged sex for money or drugs in the last 6 months (25.5% versus 2.3%). There were no gender differences in injecting risk behaviours. HIV prevalence was 38.7% (91/235) in women and 31.5% (347/1103) in men (p=0.031). HIV prevalence among female IDU who reported having exchange sex for money or drugs was 53.3% (32/60). The prevalence of HCV was 67.4% (159/236) and 73.6% (810/1101) in female and male IDU, respectively (p=0.053). After adjustment by immigrant status, age and years of injection, differences among HIV/HCV prevalence by gender were not significant. CONCLUSIONS: This study demonstrated differences in sexual risk behaviours between male and female IDU, but failed to find gender differences in injecting risk behaviours. Apart from that, the higher prevalence of HIV among women than among men, together with a lower prevalence of HCV, provides evidence that sexual transmission of HIV is important among female IDU. Additional studies are needed to analyze in-depth these specific risk factors for women in order to develop appropriate prevention and health education programs.
OBJECTIVE: To describe gender differences in injection and sexual risks behaviours, and human immunodeficiency virus (HIV) and hepatitis C (HCV) prevalence among injecting drug users (IDU) in Catalonia, Spain. METHODS: Cross-sectional studies in 2008-2009 (n=748) and 2010-2011 (n=597) in the network of harm reduction centres. Face to face interviews were conducted and oral fluid samples were collected to estimate HIV/HCV prevalence. RESULTS: Female were more likely than male IDU to have had a steady sexual partner (68.2% versus 44.9%), to have had an IDU steady sexual partner (46.6% versus 15.1%) and to have exchanged sex for money or drugs in the last 6 months (25.5% versus 2.3%). There were no gender differences in injecting risk behaviours. HIV prevalence was 38.7% (91/235) in women and 31.5% (347/1103) in men (p=0.031). HIV prevalence among female IDU who reported having exchange sex for money or drugs was 53.3% (32/60). The prevalence of HCV was 67.4% (159/236) and 73.6% (810/1101) in female and male IDU, respectively (p=0.053). After adjustment by immigrant status, age and years of injection, differences among HIV/HCV prevalence by gender were not significant. CONCLUSIONS: This study demonstrated differences in sexual risk behaviours between male and female IDU, but failed to find gender differences in injecting risk behaviours. Apart from that, the higher prevalence of HIV among women than among men, together with a lower prevalence of HCV, provides evidence that sexual transmission of HIV is important among female IDU. Additional studies are needed to analyze in-depth these specific risk factors for women in order to develop appropriate prevention and health education programs.
Authors: A Esmaeili; A Mirzazadeh; G M Carter; A Esmaeili; B Hajarizadeh; H S Sacks; K A Page Journal: J Viral Hepat Date: 2016-10-28 Impact factor: 3.728
Authors: Janni Leung; Amy Peacock; Samantha Colledge; Jason Grebely; Evan B Cunningham; Matthew Hickman; Peter Vickerman; Jack Stone; Adam Trickey; Kostyantyn Dumchev; Michael Lynskey; Lindsey Hines; Paul Griffiths; Richard P Mattick; Louisa Degenhardt; Sarah Larney Journal: J Infect Dis Date: 2019-06-05 Impact factor: 5.226
Authors: Amanda J Noska; Mary B Roberts; Carolyn Sufrin; L A R Stein; Curt G Beckwith; Josiah D Rich; Emily F Dauria; Jennifer G Clarke Journal: J Health Care Poor Underserved Date: 2016
Authors: J Reyes-Urueña; C Campbell; C Hernando; N Vives; C Folch; L Ferrer; L Fernández-López; A Esteve; J Casabona Journal: Epidemiol Infect Date: 2017-03-08 Impact factor: 4.434
Authors: Lucas Wiessing; Marica Ferri; Bart Grady; Maria Kantzanou; Ida Sperle; Katelyn J Cullen; Angelos Hatzakis; Maria Prins; Peter Vickerman; Jeffrey V Lazarus; Vivian D Hope; Catharina Matheï Journal: PLoS One Date: 2014-07-28 Impact factor: 3.240
Authors: Annemarie Rinder Stengaard; Lauren Combs; Virginie Supervie; Sara Croxford; Sarika Desai; Ann K Sullivan; Stine Finne Jakobsen; Quenia Santos; Daniel Simões; Jordi Casabona; Jeffrey V Lazarus; John B F de Wit; Frank M Amort; Anastasia Pharris; Lina Nerlander; Dorthe Raben Journal: Euro Surveill Date: 2021-11
Authors: Juliana Reyes-Urueña; M Teresa Brugal; Xavier Majo; Antonia Domingo-Salvany; Joan A Caylà Journal: BMC Public Health Date: 2015-11-13 Impact factor: 3.295
Authors: Malin Värmå Falk; Susanne Strömdahl; Anna Mia Ekström; Martin Kåberg; Niklas Karlsson; Helena Dahlborn; Anders Hammarberg Journal: Harm Reduct J Date: 2020-10-22